Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Free Cash Flow (2022 - 2026)

Sagimet Biosciences' Free Cash Flow history spans 5 years, with the latest figure at -$8.6 million for Q1 2026.

  • Quarterly Free Cash Flow rose 40.76% to -$8.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$39.7 million through Mar 2026, up 21.74% year-over-year, with the annual reading at -$45.6 million for FY2025, 7.58% down from the prior year.
  • Free Cash Flow came in at -$8.6 million for Q1 2026, up from -$11.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$3000.0 in Q2 2022 to a low of -$19.6 million in Q3 2024.
  • The 5-year median for Free Cash Flow is -$7.3 million (2022), against an average of -$8.4 million.
  • Year-over-year, Free Cash Flow crashed 190566.67% in 2023 and then skyrocketed 47.98% in 2025.
  • Sagimet Biosciences' Free Cash Flow stood at -$7.5 million in 2022, then rose by 5.43% to -$7.1 million in 2023, then crashed by 55.64% to -$11.0 million in 2024, then fell by 7.34% to -$11.8 million in 2025, then rose by 27.23% to -$8.6 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Free Cash Flow are -$8.6 million (Q1 2026), -$11.8 million (Q4 2025), and -$10.2 million (Q3 2025).